Browse Non-small cell lung cancer topic

Drug therapy subtopic

Articles 1-87 out of 87 article(s) Title Author Type Date Words ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC. May 15, 2013 2701 GTx Provides Corporate Update and Reports 2012 Financial Results. Financial report Feb 21, 2013 6181 Research and Markets: Global Non-small Cell Lung Cancer Drugs Market 2012-2016. Feb 18, 2013 670 Diabetes drug could hold promise for treating lung cancer. Jan 30, 2013 583 TechNavio Announces the Publication of Its Research Report - Global Non-Small Cell Lung Cancer Drugs Market 2012-2016. Jan 24, 2013 479 U.S. FDA Grants Priority Review to Boehringer Ingelheim's Afatinib NDA for EGFR Mutation-Positive Advanced NSCLC. Jan 15, 2013 1192 Research and Markets: Non-Small-Cell Lung Cancer (Event Driven) - Drug Development Moving Towards a Personalised Medicine Approach. Jan 10, 2013 290 Despite the Effect of Smoking Cessation Limiting Growth in the Number of Non-Small-Cell Lung Cancer (NSCLC) Cases, the Drug Market for NSCLC Will Increase to More Than $6 Billion in 2021, Fueled Largely by the Entry of Seven New Agents. Dec 4, 2012 944 Research and Markets: Global Non-small Cell Lung Cancer Drug Pipeline Capsule - 2012 Update. Nov 21, 2012 492 Astellas Submits Supplemental New Drug Application to FDA for Tarceva as a First-Line Therapy in Genetically Distinct Form of Non-Small Cell Lung Cancer. Nov 20, 2012 1026 LUNGevity Foundation Applauds FDA Approval of Abraxane as Additional Tool in Arsenal for Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Oct 12, 2012 622 Expanding Diagnosed and Drug-Treated Patient Populations Will Contribute to China's Non-Small-Cell Lung Cancer Drug Market Growth. Jul 26, 2012 560 Major Milestone Achieved in CytRx's Phase 2b Global Clinical Trial with Tamibarotene as a First-Line Treatment for Non-Small-Cell Lung Cancer. Jun 25, 2012 1219 Research and Markets: The Non-small Cell Lung Cancer Drug Market in Indonesia. Jun 20, 2012 565 For the Treatment of Non-Small-Cell Lung Cancer (NSCLC), Three-Quarters of Surveyed U.S. Oncologists Prescribe Pfizer's Xalkori Just 10 Months after the Drug's Launch. Jun 19, 2012 659 New gene signature helps in lung cancer''s treatment - reseachers. Apr 20, 2012 618 Clovis Oncology Announces Enrollment of First Patient in First Human Study of Oral EGFR Mutant-Selective Inhibitor CO-1686. Clinical report Mar 28, 2012 939 Gene variant in East Asians could explain resistance to cancer drugs. Mar 19, 2012 712 Synta Announces Review of Ganetespib Results in Lung Cancer Presented at IASLC 12th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. Financial report Feb 29, 2012 1266 Research and Markets: Lung Cancer Drug Pipeline Update 2012 Contains 426 Lung Cancer Drugs in Development, Which Have a Total of 507 Developmental Projects in Cancer. Feb 28, 2012 434 Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer. Feb 13, 2012 1120 Research and Markets: Non-small Cell Lung Cancer Drug Market in South Korea: - Adenocarcinoma, Squamous cell carcinoma and Large cell carcinoma. Jan 13, 2012 410 Russia's Non-Small-Cell Lung Cancer Drug Market Will Grow to $163 Million in 2015. Dec 14, 2011 493 Despite the Generic Erosion of Key Agents, the Non-Small-Cell Lung Cancer Drug Market Will Increase 2.5 Percent Annually Between 2010 and 2020. Dec 5, 2011 872 Randomised, open phase II study of tolerance, safety and efficacy of Viscum album extract in the palliative, additive treatment of advanced non-small cell lung carcinoma (NSCLC). Grah, Christian; Matthes, Burkhard; Happel, Helmut Report Oct 15, 2011 348 LabCorp To Offer a New Companion Diagnostic for Non-Small Cell Lung Cancer. Oct 3, 2011 760 Duodenal perforation in a patient with non-small cell lung cancer receiving Pemetrexed-Cisplatin combination. Hakeam, H.A.; O'Regan, P.J.; Al-Hshash, G.; Al-Hussieni, H. Case study Sep 1, 2011 1440 U.S. Food And Drug Administration Approves Pfizer's XALKORI[R] (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer. Aug 26, 2011 3094 FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer. Aug 26, 2011 1101 Research and Markets: Successes and Failures for Avastin (Bevacizumab) mean Mixed News for the Blockbuster Drug in the Oncology Therapeutics Market. Aug 17, 2011 639 First Gene-Targeted Drug for Melanoma Approved by FDA. Aug 17, 2011 967 Targeted drug therapy found highly effective in lung cancer treatment. Jun 4, 2011 251 Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare. May 17, 2011 1275 Global Phase III Trial With Selective c-MET Inhibitor Tivantinib (ARQ 197) Starts Enrolling Patients in Europe. Apr 18, 2011 1190 Synthetic compound may lead to drugs to fight pancreatic, lung cancer. Mar 10, 2011 298 Synta Pharmaceuticals Announces Ganetespib (STA-9090) Non-small Cell Lung Cancer Phase 2 Interim Results to be Presented at the Upcoming IASLC 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. Jan 27, 2011 765 Pfizer Initiates Rolling Submission For A New Drug Application In The U.S. For Its Fast-Tracked Investigational Compound Crizotinib (PF-02341066) For Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer. Jan 12, 2011 1303 Crizotinib shows promise against some types of NSCLC. McBride, Deborah Brief article Jan 1, 2011 270 The new drugs available. Nov 24, 2010 155 China Medical Technologies Receives SFDA Approval for its First Self-Developed PCR-based EGFR Assay for Lung Cancer Targeted Drugs. Nov 10, 2010 808 New drug shows promise against certain lung cancers. Oct 29, 2010 293 The Non-Small-Cell Lung Cancer Drug Market Will Increase From Approximately $4 Billion in 2009 to More Than $6.5 Billion in 2019. Oct 4, 2010 776 Drug slows advanced lung cancer progression in women. McBride, Deborah Brief article Oct 1, 2010 185 Gefitinib may improve progression-free survival from lung cancer. McBride, Deborah Brief article Sep 1, 2010 282 ALK inhibitor has high response in patients with NSCLC. McBride, Deborah Clinical report Aug 1, 2010 331 United Kingdom : Two new cancer treatments approved for use in the NHS. Jul 28, 2010 301 Brazil's Non-Small-Cell Lung Cancer Drug Market will Reach $240 Million by 2014. Jul 6, 2010 707 Personalized Treatments for Cancer Are Revolutionizing Patient Care. Jun 15, 2010 513 Personalized Treatments for Cancer Are Revolutionizing Patient Care. Jun 15, 2010 505 Clovis Oncology and Avila Therapeutics Sign $209 Million Partnership for the Worldwide Development and Commercialization of EGFR Mutant-Selective Inhibitor. May 25, 2010 1103 Two Studies Evaluated Full-Dose Chemotherapy Regimen and Concurrent Radiation in Treatment of Lung Cancer. May 20, 2010 1979 Synta Presents STA-9090 NSCLC data at the IASLC 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. Feb 26, 2010 930 Research and Markets: Lung Cancer Drug Pipeline Update 2010. Jan 29, 2010 392 OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer. Nov 16, 2009 758 Cetuximab drug with chemo may cut death risk in lung cancer patients. Sep 22, 2009 310 Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents. Sep 18, 2009 1449 OSI Pharmaceuticals Inc. Brief article Aug 10, 2009 241 Oncothyreon Inc (Belleview WA) said a long-term follow-up study showed that prolonged treatment with its cancer vaccine Stimuvax was well-tolerated among patients with non-small cell lung cancer, sending its shares up 55%. Brief article Aug 10, 2009 151 Death rates increased in lung cancer patients undergoing HRT. Brief article Jun 16, 2009 155 Medarex Announces Efficacy Data in Cancer Patients Treated with Investigational Anti-PD-1 Antibody at American Society of Clinical Oncology Annual Meeting. Jun 1, 2009 1309 Research and Markets: Cancer Drug Discoveries: What the Future Holds for the Non-Small Cell Lung Cancer Market and Therapeutic Approaches. May 26, 2009 774 mTOR as a validated cancer target. Brief article May 1, 2009 191 Encouraging Results Published on Use of TomoTherapySM in Lung Cancer Treatment. Apr 9, 2009 1115 Research and Markets: Lung Cancer Drug Pipeline Update 2009. Mar 4, 2009 368 Popular cancer drug 'increases blood clot risk'. Dec 3, 2008 458 Efficacy of cisplatin and vinorelbine in patients with metastatic non-small cell lung carcinoma/ Metastatik kucuk hucreli disi akciger karsinomlu hastalarda sisplatin ve vinorelbinin etkinligi. Yilmaz, Ufuk; Halilcolar, Huseyin; Yildirim, Yasemin; Yapicioglu, Sena; Unsal, Ipek; Mahlec, Ceyda Clinical report Dec 1, 2008 2750 Popular cancer drug 'increases blood clot risk'. Nov 25, 2008 458 Two drugs don't boost lung cancer survival: Roche. Oct 6, 2008 468 Manage patients with non-small cell lung cancer: as seen in the Clinical Journal of Oncology Nursing. Becze, Elisa Oct 1, 2008 947 Important Updates to the NCCN Drugs & Biologics Compendium(TM) Non-Small Cell Lung Cancer. Sep 10, 2008 679 Biomarkers allow doctors to match therapy to patient. Conference news Sep 1, 2008 216 Biothera Drug Synergistic with Avastin(R) Against Cancer, Study Finds. Feb 28, 2008 497 Preclinical Data Published in Cancer Science Show AVEO's Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers. Nov 13, 2007 722 Biothera's Imprime PGG Increases Efficacy of Erbitux against Non-Small Cell Lung Cancer, Study Finds. Sep 11, 2007 959 Drug lengthened survival in non-small-cell lung ca. Lovinger, Sarah Pressman Clinical report Jul 1, 2007 491 Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial. Jun 12, 2007 912 Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer. Financial report Jun 3, 2007 756 Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer. Clinical report Jun 2, 2007 2826 Drug review disappoints; The World Today. Mar 9, 2007 215 Eli Lilly & Co's (Indianapolis IN) Alimta was rejected by a UK government panel for treating a form of lung cancer because it wasn't as cost-effective as Sanofi-Aventis SA's older medicine Taxotere or the best supportive care. Brief article Feb 19, 2007 147 Talactoferrin Alpha receives fast-track designation for the treatment of non-small cell lung cancer. McBride, Deborah Jan 1, 2007 603 Antiangiogenesis drug gets nod for unresectable lung ca. Mechcatie, Elizabeth Nov 15, 2006 579 Novelos Therapeutics Obtains FDA Fast Track Designation for NOV-002 Lung Cancer Treatment. Aug 7, 2006 758 Hana Biosciences Initiates Phase I Clinical Trial of a Targeted Chemotherapy Agent for Patients With Advanced Solid Tumors. Aug 3, 2006 1017 New antiangiogenesis agents fight lung cancer. MacNeil, Jane Salodof Aug 1, 2006 947 Bevacizumab-erlotinib combo boosts lung cancer survival. MacNeil, Jane Salodof Aug 1, 2006 595 Survival not better with chemo for early NSCLC. MacNeil, Jane Salodof Aug 1, 2006 637